XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Common stock
Retained earnings
Accumulated other comprehensive income (loss)
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2020   21,796,904    
Beginning balance at Dec. 31, 2020 $ 717,750 $ 278,505 $ 403,888 $ 35,357
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 85,990   85,990  
Share-based compensation expense 2,557 $ 2,557    
Common stock issued - Option exercise; stock grants (in shares)   245,630    
Common stock issued - Option exercise; stock grants 2,383 $ 2,383    
Other comprehensive income (loss) (13,264)     (13,264)
Dividends declared on common stock (16,171)   (16,171)  
Common stock repurchased (in shares)   (1,595,886)    
Common stock repurchased (68,869) $ (27,364) (41,505)  
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2021   20,446,648    
Ending balance at Sep. 30, 2021 710,376 $ 256,081 432,202 22,093
Common stock shares outstanding, beginning balance (in shares) at Jun. 30, 2021   20,791,659    
Beginning balance at Jun. 30, 2021 708,731 $ 260,774 420,111 27,846
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 27,170   27,170  
Share-based compensation expense 892 $ 892    
Common stock issued - Option exercise; stock grants (in shares)   52,265    
Common stock issued - Option exercise; stock grants 339 $ 339    
Other comprehensive income (loss) (5,753)     (5,753)
Dividends declared on common stock (5,259)   (5,259)  
Common stock repurchased (in shares)   (397,276)    
Common stock repurchased (15,744) $ (5,924) (9,820)  
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2021   20,446,648    
Ending balance at Sep. 30, 2021 $ 710,376 $ 256,081 432,202 22,093
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2021 20,085,336 20,085,336    
Beginning balance at Dec. 31, 2021 $ 715,339 $ 249,856 444,343 21,140
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 58,039   58,039  
Share-based compensation expense 3,239 $ 3,239    
Common stock issued - Option exercise; stock grants (in shares)   130,546    
Common stock issued - Option exercise; stock grants 0      
Other comprehensive income (loss) (127,071)     (127,071)
Dividends declared on common stock (20,435)   (20,435)  
Common stock repurchased (in shares)   (1,498,325)    
Common stock repurchased $ (76,322) $ (27,370) (48,952)  
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2022 18,717,557 18,717,557    
Ending balance at Sep. 30, 2022 $ 552,789 $ 225,725 432,995 (105,931)
Common stock shares outstanding, beginning balance (in shares) at Jun. 30, 2022   18,712,789    
Beginning balance at Jun. 30, 2022 580,767 $ 224,776 419,254 (63,263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 20,367   20,367  
Share-based compensation expense 942 $ 942    
Common stock issued - Option exercise; stock grants (in shares)   4,328    
Common stock issued - Option exercise; stock grants 0 $ 0    
Other comprehensive income (loss) (42,668)     (42,668)
Dividends declared on common stock (6,638)   (6,638)  
Common stock repurchased (in shares)   440    
Common stock repurchased $ 19 $ 7 12  
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2022 18,717,557 18,717,557    
Ending balance at Sep. 30, 2022 $ 552,789 $ 225,725 $ 432,995 $ (105,931)